v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (22,261,338) $ (22,659,480)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,669,782 652,732
Amortization of loan discount and fees 4,610,234 682,956
Stock-based compensation 491,945 4,155,641
Fees incurred in connection with debt financings 48,245 132,609
Change in fair value of warrant liability (18,223) 21,930
Change in fair value of derivative liability (794,477) 627,956
Change in fair value of contingent consideration 6,418,355 7,039,394
Forgiveness of Payroll Protection Program (1,760,755)  
Deferred income tax benefit   (1,100,120)
Change in credit reserve (26,429) 66,748
Changes in operating assets and liabilities:    
Accounts receivable, net (289,061) (32,582)
Due from factor, net 433,671 (540,257)
Inventory 100,006 (483,477)
Prepaid expenses and other current assets (522,434) (1,259,835)
Accounts payable 382,943 749,352
Accrued expenses and other liabilities 1,715,221 451,298
Deferred revenue 119,977 (78,492)
Accrued compensation - related party   (108,550)
Accrued interest 992,482 206,163
Net cash used in operating activities (8,689,857) (11,476,015)
Cash flows from investing activities:    
Cash acquired (consideration) pursuant to business combination   (5,442,966)
Purchase of property, equipment and software (5,533) (13,585)
Deposits   (67,431)
Net cash used in investing activities (5,533) (5,523,982)
Cash flows from financing activities:    
Proceeds (repayments) from related party advances (162,692)  
Advances (repayments) from factor (60,735) (39,520)
Proceeds from venture debt 237,500  
Issuance of loans payable 248,858 2,626,050
Repayments of convertible and promissory notes (3,068,750) (2,002,731)
Issuance of convertible notes payable 3,751,250 5,078,650
Proceeds from initial public offering 9,347,450 10,000,002
Exercise of over-allotment option with public offering, net   1,364,997
Exercise of warrants   1,768,046
Offering costs (1,930,486) (2,116,957)
Net cash provided by financing activities 8,362,395 16,678,537
Net increase in cash and cash equivalents (332,995) (321,460)
Cash and cash equivalents at beginning of period 528,394 575,986
Cash and cash equivalents at end of period 195,399 254,526
Supplemental disclosure of cash flow information:    
Cash paid for interest 318,576 460,179
Supplemental disclosure of non-cash investing and financing activities:    
Conversion of notes into common stock 1,802,372 2,680,289
Right of use asset 152,387  
Warrants issued in connection with note 790,540  
Derivative liability in connection with convertible note 559,957 1,858,887
Conversion of related party notes and payables into preferred and common stock 25,000 257,515
Conversion of venture debt into preferred stock $ 6,300,000  
Conversion of preferred stock into common stock   6,293
Common shares issued pursuant to equity line of credit   $ 367,996